Cardiometabolic interventions - focus on transcriptional regulators

Joshua T. Chai; Choudhury, Robin P.
May 2013
European Journal of Cardiovascular Medicine;2013, Vol. 2 Issue 3, p212
Academic Journal
Cardiovascular disease (CVD) remains the largest healthcare burden in the Western world; and the increasing prevalence of type II diabetes mellitus, at least partially driven by a trend in lifestyle changes associated with global economic development, is likely to fuel this CVD burden worldwide. Over the past two decades, there has been an increased awareness of the convergence of risk factors contributing to both cardiovascular disease and diabetes leading to the concept of the metabolic syndrome, and the realisation of the opportunity to intervene at this intersection to simultaneously target CVD and metabolic dysfunction. This brings together the fields of cardiovascular medicine, diabetology, and increasingly clinical immunology for a unified and concerted effort to reduce risk for both conditions simultaneously. The discovery of the targeted pathways of drugs already in clinical use such as fibrates and thiazolidinediones (TZD) has led to accelerated basic and clinical research into selective and dual PPAR-α and PPAR-γ agonists, which can theoretically target glucose, lipid and lipoprotein metabolism, as well as potentially exerting inhibitoryeffects in vascular inflammation, all of which might be predicted to reduce atherosclerosis. In this article, we will discuss the basic science as well as recent clinical development in the pursuit of optimal cardiometabolic intervention along with insight into strategies for future drug development.


Related Articles

  • Factor analysis of metabolic syndrome using direct measurement of insulin resistance in Chinese with different degrees of glucose tolerance. Chung-Ze Wu; Jiunn-Diann Lin; Jer-Chuan Li; Fone-Ching Hsiao; Chang-Hsun Hsieh; Shi-Wen Kuo; Yi-Jen Hung; Chieh-Hua Lu; Chih-Tuseng He; Dee Pei // Indian Journal of Medical Research;Apr2008, Vol. 127 Issue 4, p336 

    Background & objectives: With the increasing prevalence of type 2 diabetes and cardiovascular disease in Taiwan, the understanding of metabolic syndrome (MetS) becomes more important. The purpose of this study was to investigate the clustering patterns of the risk variables of the MetS with...

  • Metabolic syndrome & Framingham Risk Score: Observations from a coronary angiographic study in Indian patients. Khanna, Roopali; Kapoor, Aditya; Kumar, Sudeep; Tewari, Satyendra; Garg, Naveen; Goel, Pravin K. // Indian Journal of Medical Research;Feb2013, Vol. 137 Issue 2, p295 

    Background & objectives: Metabolic syndrome (MS) is an important determinant of cardiovascular (CV) risk. Framingham Risk Scores (FRS) often underestimate the CV risk in Asians, younger patients and those with MS. Asians often develop coronary artery disease (CAD) at a younger age and also have...

  • Advancing drug therapy of the metabolic syndrome. Grundy, Scott M // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p341 

    The metabolic syndrome — a group of factors that raise the risk of cardiovascular disease and type 2 diabetes — is increasingly common. How might the challenges of developing improved therapies to normalize these risk factors be approached?

  • Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Hayden, Melvin R.; Tyagi, Suresh C. // Nutrition & Metabolism;2004, Vol. 1, p10 

    Background: The topical role of uric acid and its relation to cardiovascular disease, renal disease, and hypertension is rapidly evolving. Its important role both historically and currently in the clinical clustering phenomenon of the metabolic syndrome (MS), type 2 diabetes mellitus (T2DM),...

  • Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Monami, Matteo; Lamanna, Caterina; Balzi, Daniela; Bartalucci, Francesca; Melani, Cecilia; Masotti, Giulio; Marchionni, Niccolô; Mannucci, Edoardo // Journals of Gerontology Series A: Biological Sciences & Medical ;Jun2008, Vol. 63 Issue 6, p646 

    Background. Although age does not seem to modify the association of the metabolic syndrome (MS) with cardiovascular risk in middle-aged individuals, no comparison of risks associated with MS between old and middle-aged persons has been reported so far. Methods. An observational study was...

  • Links between Metabolic Syndrome and Cardiovascular Autonomic Dysfunction. Garruti, G.; Giampetruzzi, F.; Vita, M. G.; Pellegrini, F.; Lagioia, P.; Stefanelli, G.; Bellomo-Damato, A.; Giorgino, F. // Experimental Diabetes Research;2012, Special section p1 

    Background. Type 2 diabetes (T2D) might occur within metabolic syndrome (MbS). One of the complications of T2D is an impaired (imp) cardiovascular autonomic function (CAF). Aims. In subjects with T2D and age ≤ 55 years, the prevalence of impCAF and its relationship with BMI, waist, HbA1c...

  • Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Wong, S. P. Y.; Huda, M.; English, P.; Bargiotta, A.; Wilding, J. P. H.; Johnson, A.; R. Corrall; Pinkney, J. H. // Diabetologia;Dec2005, Vol. 48 Issue 12, p2641 

    Aims/hypothesis: Familial partial lipodystrophy (FPLD) and obesity are both associated with increased risks of type 2 diabetes and cardiovascular disease. Although adipokines have been implicated, few data exist in subjects with FPLD; therefore we investigated a family with FPLD due to a lamin...

  • The prevalence of metabolic syndrome and its predominant components among pre-and postmenopausal Ghanaian women. Arthur, Fareed Kow Nanse; Frimpong, Michael Adu; Yeboah, James Osei; Mensah, Faustina Obu; Owusu, Lawrence // BMC Research Notes;2013, Vol. 6 Issue 1, p1 

    Background Metabolic Syndrome (MetS) is a clump of risk factors for development of type 2 diabetes mellitus and cardiovascular diseases. Menopause and age are thought to predispose women to the development of metabolic syndrome. This study aimed to estimate the prevalence of MetS and identify...

  • METABOLIC SYNDROME IN CLINICAL PRACTICE: CONSIDERATIONS ON DIAGNOSTIC CRITERIA AND PREVALENCE. Vasilescu, R. // Therapeutics, Pharmacology & Clinical Toxicology;2011, Vol. 15 Issue 2, p93 

    The metabolic syndrome is defined as an association of risk factors of metabolic origin, combined with a heightened risk for cardiovascular diseases and for type 2 diabetes mellitus. The pathogenesis of the metabolic syndrome is multifactorial, the main risk factors being: obesity (abdominal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics